Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials

Executive Summary

Agency officials, industry and academia contemplate a new approach to gauging drug-induced liver injury by using individual patients’ baseline liver enzyme measurements, a move that some say could eliminate problems with the use of the upper limit of normal and allow for the assessment of DILI in cases where there is underlying liver injury.

Advertisement

Related Content

Jurassic Products: FDA Resurrects Withdrawn Drugs To Study Liver Injury
FDA Liver Injury Conference Another Chance To Inform Guidance Changes
Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals
Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals
FDA Panel To Weigh Unmet Need Vs. Liver Injury With Samsca Kidney Indication
FDA Prepares To Update Drug-Induced Liver Injury Guidance

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055246

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel